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Antimicrobial resistance (AMR) in humans is inter-linked with AMR in other
populations, especially farm animals, and in thewider environment. The rela-
tively few bacterial species that cause disease in humans, and are the targets of
antibiotic treatment, constitute a tiny subset of the overall diversity of bacteria
that includes the gut microbiota and vast numbers in the soil. However, resist-
ance can pass between these different populations; and homologous resistance
genes have been found in pathogens, normal flora and soil bacteria. Farm ani-
mals are an important component of this complex system: they are exposed to
enormous quantities of antibiotics (despite attempts at reduction) and act as
another reservoir of resistance genes. Whole genome sequencing is revealing
and beginning to quantify the two-way traffic of AMR bacteria between the
farm and the clinic. Surveillance of bacterial disease, drug usage and resistance
in livestock is still relatively poor, though improving, but achieving better anti-
microbial stewardship on the farm is challenging: antibiotics are an integral
part of industrial agriculture and there are very few alternatives. Human pro-
duction and use of antibiotics either on the farm or in the clinic is but a recent
addition to the natural and ancient process of antibiotic production and resist-
ance evolution that occurs on a global scale in the soil. Viewed in this way,
AMR is somewhat analogous to climate change, and that suggests that an
intergovernmental panel, akin to the Intergovernmental Panel on Climate
Change, could be an appropriate vehicle to actively address the problem.1. Introduction
Human medicine is predominantly concerned with antimicrobial resistance
(AMR) in human pathogens, but this is a very narrow view. Across all habitats,
the total number of bacteria species alone may exceed one million [1] and only a
tiny fraction of these, some 10–20 species such as Mycobacterium tuberculosis or
Staphylococcus pneumoniae, are specialist human pathogens [2]. A somewhat
larger number, several hundred species, are opportunistic pathogens that only
cause human disease in certain circumstances, such as Listeria spp., Campylobacter
spp. or Staphylococcus aureus. Hundredsmore are part of the normal humanmicro-
biota, the majority of which are commensals that have not been linked to disease
[3]. Many of the pathogenic bacteria (and probably many of the commensals too)
occur not only in humans but also in other hosts, a wide variety of livestock and
wildlife species (that is, theyare zoonotic) or in thewider environment (sapronotic)
or both, Escherichia coli being an obvious example [2].
The interplay between these different ecologies is especially important in the
context of antibiotic resistance (figure 1). There are multiple links between the
human, animal and environmental compartments that allow not only movement
of the bacteria but also of mobile genetic elements (MGEs) and the drugs them-
selves [4]. The picture becomes even more complex when we also consider that
antimicrobials affect more than one microbe species (the ‘multi-drug, multi-bug’
problem) and that resistance routinely moves between microbe species via MGEs.
Ideally, we need a sufficiently detailed, quantitative understanding of the
dynamics ofmultiple bacteria,multiple drugs andmultiple resistancedeterminants
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Figure 1. Diagrammatic representation of the routes of transmission of AMR between farm animals, the wider environment and humans. Reprinted with permission
from [4] (Credit: P. Huey/Science).
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useful predictions. For example, we might reasonably ask: if
wewere to ban the use of an antimicrobial drug in farm animals
whatwould be the impact on levels of resistance in human clini-
cal cases? We still are a long way from being able to give robust
answers to that kind of question. However, recentmethodologi-
cal advances point toways to improve our understanding of the
factors affecting levels of AMR in different host species. For
example, phylogenetic analysis of bacterial genome sequences
can be combined with epidemiological data by mapping traits
such asAMRprofile andhost speciesontobacterial phylogenies.
Here, we appraise four aspects of this challenging topic.
First, we review the evidence that links AMR in different
microbial populations in humans, other animals (especially
livestock) and the wider environment. Second, we illustrate
how state-of-the-art phylodynamic analysis can inform the
evidence base. Third, we consider ways of reducing AMR
within livestock populations. Finally, we reflect upon how
we might achieve effective global governance of AMR that
recognizes the importance of medicine, veterinary medicine
and environmental microbiology.2. Sources of resistance
(a) Commensals
The advent of metagenomics has provided insights into the
make-up of the human gut flora. One study found numerous
resistance genes in the unculturable fraction, the so-called
microbial ‘dark matter’ that comprises the bulk of the gut flora,
but these were not homologous with resistance genes of clinical
relevance [5]. By contrast, the culturable fraction contained
numerous homologues of resistance genes in pathogenic bac-
teria. However, the direction of transfer between the
commensal gut flora and the pathogens is uncertain.(b) Soil
The global biomass of microbes is enormous. A crude calcu-
lation consistent with published estimates [6] gives a value of
approximately 50 tonnes of bacteria per person. Most of this
biomass is found in soil, and soil is also the original source of
the majority of antibiotics used in medicine and veterinary
medicine [7]. Soil bacteria, and other soil microbes, have
been producing antibiotics on a global scale for perhaps
2 billion years [8].
It is therefore not surprising that soil is also a major reser-
voir of AMR: resistance is likely to be as natural, widespread
and ancient as antibiotic production. The relationship between
resistance to naturally produced antibiotics in the soil andman-
ufactured antibiotics in the clinic, however, remains unclear.
For example, one recent metagenomics study found multiple
examples of resistance genes in the soil that had 100% hom-
ology to those found in clinical isolates, across all major
classes of antibiotics [9]. That study provides clear evidence
for horizontal gene transfer between soil bacteria and patho-
gens, but it does not reveal in which direction(s) this has
taken place. For example, the observation that resistance deter-
minants for synthetic quinolones (qnr genes) can be detected in
soil seems to indicate transfer from, not to, the clinic.
(c) Farm animals
Industrial agriculture in its present form relies heavily on the
widespread use of antimicrobials to improve animal health, wel-
fare andproductivity.Antimicrobials are used on livestock farms
foranumberof reasons: (i) as therapeutics; (ii)more commonlyas
metaphylactics, meaning that the presence of clinical illness in
one animal triggers drug treatment of the whole herd or flock;
(iii) prophylactics; and (iv) growth promotion. In Europe, antimi-
crobial usage is particularly high in intensively farmed species
such as pigs and poultry and less so in extensively farmed
cattle and sheep [10]. The list of antibiotics regarded as ‘critically
important’ for farm livestockby theOIE (theWorldOrganization
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Figure 2. Sales of antibiotics for veterinary use in Europe, 2005–2009, for
third and fourth generation cephalosporins ( purple) and fluoroquinolones
(blue). Units are milligram per population correction unit (¼1 kg). In
2006, an EU-wide ban on the use of antibiotics as growth promoters was
introduced. Data from [10].
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antibiotics used in human medicine [11].
Growth promotion is a particularly controversial issue.
It has been used extensively since the 1950s and has been
reported to increase weight gain by up to 15–20%, a very-
significant effect [12]. The mechanism underlying growth
promotion remains uncertain [13]; it works for antibacterials
but not antifungals or antivirals, and it works for a variety of
animal species including human children [14].
A ban on the use of growth promoters was implemented
throughout the EU in 2006. However, this has not led to any
consistent decrease in antibiotic consumption (figure 2). Typi-
cally, the growth promoter ban has prompted compensatory
increases in metaphylactic and prophylactic use. The result is
that in Europe, the volume of agricultural usage of antibiotics
continues to rival that of medical usage and in the USA
(which recently introduced a voluntary ban on growth pro-
moters), agricultural usage exceeds medical usage [15].
However, there have been some localized successes: for
example, a more than 50% reduction in the usage of anti-
biotics (notably macrolides) in pigs was achieved from 1992
to 2008 in Denmark without any loss in productivity [16].
The key question regarding antimicrobial use in farm ani-
mals is whether and to what degree it poses a threat to
human health. There are surprisingly few published studies
which directly address this question. We know from numer-
ous observational studies and surveillance reports that AMR
is widespread in farm animals. Examples include: apramycin
and ampicillin-resistant E. coli in newborn calves [17–20];
equally high levels of ampicillin resistance on organic farms
[21]; and, more recently, the first reports of carbapenem-
resistant enterobacteria in livestock [22]. However, such studies
do not establish the direction ofmovement (if any) of resistance
between human and livestock populations. Carbapenems, for
instance, are not used in livestock so resistancewas presumably
imported from another, likely human, source. Bans on the use
of avoparcin in animal feed in European countries in the 1990s
were followed by reductions (by 75% in one German state) in
levels of vancomycin-resistant enterococci in food products
and in carriage in healthy humans [23]. But, in general, the
benefits of reduced antimicrobial use in farm animals for
human health remain unquantified.3. Evidence from sequence data
Phylogenetic evidence has previously been used to determine
the evolutionary origins of pathogen lineages in both human
and livestock populations. A key feature of these kinds of analy-
sis is that ancestral relationships may be inferred. For example,
based on analysis of concatenated multi locus sequence type
sequence data, it was concluded that MRSA lineage ST5 disse-
minated globally in poultry after a cross-species transmission
from humans [24].
The high genetic resolution provided by whole genome
sequencing (WGS) provides a rich resource for inferring patho-
gen movements between host populations. Analysis of WGS
data suggests that another MRSA lineage, CC97, has entered
the human population from a livestock source on more than
one occasion over the past 100 years [25]. A study of S. aureus
CC398 fromhumans and livestock [26] has provided quantitat-
ive evidence that livestock-to-human jumps have occurred
more frequently than human-to-livestock jumps over the evol-
utionary history of that lineage, consistent with CC398 being
regarded as a livestock acquiredMRSA (althoughwith a separ-
ate clade associated with human-to-human transmission)
(figure 3a). A similar study of Salmonella Typhimurium
DT104 indicated multiple jumps between human and cattle
populations over the past five decades as well as significant
spread within human populations, which was unexpected as
this is regarded as a food-borne pathogen [27].
In a novel analysis using WGS data, Ward et al. [26] were
also able to quantify the gain and loss of specific antibiotic
resistance determinants across the evolutionary history of
MRSA CC398 (figure 3b). The analysis showed that methicil-
lin resistance was gained and lost substantially more often
than tetracycline resistance, and also indicated significant
differences in numbers of gains and losses of two different
tetracycline resistance determinants, tetK and tetM, consistent
with their modes of inheritance.
Analysis of discrete traits upon phylogenies, e.g. as
implemented in the BEAST software [28,29] and used in the
aforementioned studies, provides a framework for inferring
the nature and timing of character changes over the evol-
utionary histories of pathogens [30–32]. Such methods have
great potential to improve our understanding of the factors
influencing the gain and loss of resistance in natural popu-
lations, both through the movement of the pathogens
themselves or the de novo appearance of resistance determi-
nants. Their full power will be harnessed in the future
through computational developments to allow larger num-
bers of bacterial whole genome sequences to be analysed,
as well as by explicitly incorporating antimicrobial usage data
and by analysing multiple traits (e.g. resistance phenotype
and host species) simultaneously. Ultimately, however, this
kind of analysis is entirely dependent on the availability of
an appropriate selection of pathogen genomes. Sample collec-
tion needs to have spanned an appropriate time period
and geographical range and, importantly, needs to cover all rel-
evant host populations and reflect the phenotypic diversity
of strains (e.g. in terms of resistance profile). In many instan-
ces, sampling is heavily biased towards humans, making
the role of non-human reservoirs difficult or impossible to
evaluate. This is one of several reasons to ensure that surveil-
lance and monitoring are properly coordinated across
different sectors and that sample collections are accompanied
by appropriate metadata.
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Figure 3. Discrete traits analysis of S. aureus CC398. Adapted and reprinted with permission from [26]. (a) Frequency of host jumps between human and livestock
populations. (i) Staphylococcus aureus CC398 core genome BEAST maximum clade credibility tree with discrete-trait mapping by host. Branches are coloured accord-
ing to inferred ancestral host (human or livestock). (ii) The inferred number of transitions between human and livestock hosts across 9000 BEAST phylogeny samples
are plotted (95% highest posterior density intervals and medians shown as horizontal lines). (b) Frequency of gain and loss of mecA, a determinant of methicillin
resistance for S. aureus CC398. (i) Staphylococcus aureus CC398 core genome BEAST maximum clade credibility tree with discrete-trait mapping for presence or
absence of mecA. Branches are coloured according to inferred ancestral state (mecA absent or present). (ii) The inferred number of gains (transitions from absence
to presence of mecA) or losses (transitions from presence to absence of mecA) across 9000 BEAST phylogeny samples are plotted (95% highest posterior density
intervals and medians shown as horizontal lines).
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(a) Surveillance
An important step towards assessing any threat to public health
fromAMR in farmanimals is to determine levels of resistance in
those populations. Yet there has been no systematic, inter-
national review of levels of AMR in farm animals. This aspect
was ignored by the recent World Health Organisation (WHO)report on AMR globally [33] and the OIE and FAO (the inter-
national agencies with responsibility for livestock) have yet to
conduct a similar exercise. Some countries, notably Denmark,
have instigated coordinated reporting of AMR in humans and
livestock [34] and the need for coordination is also recognized
in the UK [35]. However, these remain exceptions.
National level reporting of AMR in farm animals typi-
cally relies on passive surveillance. For AMR in humans,
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These include open source reporting (e.g. ProMED or Health-
Map [36]) and the identification of global hotspots where
active surveillance might be targeted [37]. In principle,
these kinds of approaches could be extended to farm animals,
as has been suggested in the context of emerging zoonotic
diseases in general [38].
(b) Reducing antimicrobial usage in farm animals
Reducing the levels of antimicrobial consumption in farm ani-
mals has not proved straightforward, as the experience of the
EU-wide ban on growth promoters illustrates (see §2c). Outside
Europe, the adoption of voluntary codes and the development
of guidelines for drug use, while welcome in themselves, seem
unlikely to reduce consumption dramatically.
There may be some potential for more effective use of
antimicrobials in farm animals, particularly if this generated
tangible benefits in terms of reduced costs or improved pro-
ductivity. These include the same approaches that have
been proposed for human medicine, such as overkill strat-
egies, combination therapies and drug reuse and recycling
(e.g. [39]). Again as for humans, there would be obvious
advantages of rapid diagnosis of bacterial infections and
real-time profiling of resistance determinants using whole
genome sequence data (e.g. [40,41]) to determine treatment
strategies more quickly and accurately.
A complete ban on the use of antimicrobials in farm ani-
mals would inevitably have serious repercussions for animal
health, welfare and productivity, and consequently on food
prices. At present, it would be extremely hard to justify such
an action in terms of the expected benefit to human health,
given that the evidence for a direct link is so inconclusive
(see §2c). However, reduced antimicrobial consumption in
farm animals could form part of a coordinated strategy
across the different sectors [35]. Any adverse effects of this on
the agricultural industry would be at least partially alleviated
if viable alternatives to antimicrobials were available.
(c) Alternatives to antimicrobials for farm animals
The range of potential alternatives to antimicrobials in farm
animals [42] is, for the most part, the same as for humanmedi-
cine. There are currently a number of prebiotics and probiotics
available, though their efficacy is unclear and likely variable.
Mixing the two has also been proposed, so-called ‘synbiotics’.
Phage therapy can be effective, for example against Salmonella
Typhimurium in poultry and pigs, although this requires rapid
selection and administration of the phage and high bacterial
loads [42]. It may be possible to use purified phage lysins
directly rather than the phage itself, thus precluding unin-
tended transfer of genetic material from the phage. However,
none of these possibilities is close to being available for com-
mercial use on a global scale against the full spectrum of
microbial disease in farms animals.
A more immediately practical proposition may be to
expand the range of vaccines available for veterinary use.
Although vaccines are already available against many of
the major viral diseases of livestock, there is currently limited
routine use of vaccines that protect against bacterial infection
and disease. Even when it is available, a vaccine is not auto-
matically adopted by producers: for example, one trial of a
live oral Lawsonia vaccine in pigs resulted in both 80%
lower consumption of oxytetracycline and increasedproductivity [43], but the vaccine is not widely used. As
long as antibiotics are still available and effective, there is
arguably little commercial incentive either to use existing or
to develop new antibacterial vaccines for farm animals.
A longer term vision for reducing antimicrobial usage in
farm animals might include the use of livestock that are
genetically resistant to infection or disease, likely through
the use of genetic modification technologies. One example
of early progress in this direction comes from the develop-
ment of transgenic chickens that do not transmit avian
influenza [44].
Overall, however, it is clear that therewould need to be con-
siderable investment in research and development before any
of the above approaches to disease control in farm animals
become effective replacements for antimicrobials.5. Discussion and recommendations
As recently pointed out [45], the challenge of tackling AMR has
a number of parallels with the challenge of tackling another
twenty-first century crisis, climate change. Both AMR and
climate change are natural processes operating on a global
scale that human activity has influenced only in the past
half-century or so. However, there are also some important
differences. In the context of climate change, alternatives to
the burning of fossil fuels are already available and are begin-
ning to be adopted on a significant scale. By contrast, as
pointed out in §4c, alternatives to antimicrobials are not so far
advanced. In the context of climate change, evidence-based tar-
gets for reductions in carbon dioxide emissions have been
developed and agreed. By contrast, there are no agreed targets
for reductions in antimicrobial usage, nor does the evidence
base exist that could beused to set them.Humans currently pro-
duce, use andmisuse an estimated 175 000 tonnes of antibiotics
per year [15], but it is not even clear whether any level of anti-
microbial usage is sustainable in the long term; many regard
the emergence of AMR as inevitable. Finally, in the context of
climate change, an international body, the Intergovernmental
Panel on Climate Change, has been set up to marshal the scien-
tific evidence and inform policy-making. There is currently no
equivalent for AMR.
The case for an intergovernmental panel, or similar initiat-
ive, to tackle AMR comes from the realization that the problem
is global and cross-sectorial, encompassing medicine, agricul-
ture and the wider environment and so cutting across the
remit of multiple international agencies including the WHO,
OIE/FAO and UN [45]. There is a clear need for research
input from a range of disciplines, not only clinical and veterin-
ary medicine, epidemiology, microbiology and pharmacology,
but also health economics, international law and social science.
However, effective action on AMR will require a coordinated
response from governments, industry and international
agencies as well as scientists. That action will need to involve
and will affect clinicians, pharmacists, patients, veterinarians
and farmers, all of whom have contributed to the current
AMR problem and all of whomwill be part of a long-term sol-
ution. The most immediate need is to develop strategies for
improved antimicrobial stewardship (in both human medicine
and industrial agriculture), reinvigorate the antimicrobial drug
pipeline and to develop effective and sustainable alternative
approaches to tackling microbial disease in both humans
and livestock.
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